Lucida Medical

Leading AI solution for prostate cancer pathway optimization

[Lucida Medical @LucidaMedical]

Heading to BAUS 2026!

Find us at Booth 25 and learn more about our work on AI‑supported MRI pathways, including our contribution to the IP1‑PROSTAGRAM study (P17‑2, 17 June).

Looking forward to connecting!

#BAUS @BAUSurology

[Lucida Medical @LucidaMedical]

June is a busy month for us!

Meet us in Leeds (2 June), Derby (4 June), Liverpool for #UKIO (8–10 June), London for #BAUS (15–17 June, Booth 25) and #RCR AI (29–30 June, Booth 4).

Looking forward to seeing colleagues across the UK!

[Lucida Medical @LucidaMedical]

A great #BSUR2026 in Birmingham!

Insightful discussions on AI in prostate cancer pathways following Dr Antony Rix’s session, and valuable conversations at the booth about Pi™ in everyday reporting.

Thank you to the BSUR community for the warm engagement!

[Lucida Medical @LucidaMedical]

A look back at our Sips & Insights evening in Kraków!

Dr Luca Russo (@lrusso_md) shared his experience with Prostate Intelligence (Pi™), sparking a great discussion among colleagues about AI in the prostate cancer pathway. Thank you to everyone who joined us 🙌

[Lucida Medical @LucidaMedical]

Lucida Medical is heading to BSUR in Birmingham!

Join Dr Antony Rix on 21 May, 13:15–13:45 for insights on AI in prostate cancer pathways.

Visit us at Booth 1 or book a meeting: https://t.co/XPM4xiL2pJ

[Health Innovation West Midlands @HealthInnovWM]

We’re pleased to announce the nine high-potential innovators selected for the Grow #DigitalHealth Midlands 2026 cohort delivered in collaboration by @Healthinn_em & HIWM.

Meet the innovators: https://t.co/NR4HsAbsWm

#HealthInnovation #NHS #MedTech #WestMidlands #EastMidlands

[The British Society of Urogenital Radiology @BSUroRad]

BSUR are super excited about the upcoming conference in Birmingham
Thanks to all the great sponsors below who enable us to put on such a great event
@LucidaMedical @CanonUKandIE @HLHImagingGroup @ArgonMedical @QuibimBiomarker @Bayer @SiemensHealth @QuibimBiomarker @DeepHealthEU

[Lucida Medical @LucidaMedical]

Following last week’s software release, we’re highlighting one of the updates designed to make clinicians’ work easier: segmentation editing.

Pi™ lets clinicians adjust, remove or draw lesion segmentations before sending to PACS, giving more control and a faster workflow.

[Lucida Medical @LucidaMedical]

Lucida Medical is now a member of AXREM, the UK’s leading association for imaging, radiotherapy, healthcare IT and care equipment.

We’re excited to collaborate with fellow members, advance patient outcomes, and contribute to the AXREM AI Special Focus Group!

[Lucida Medical @LucidaMedical]

Learn more about the research paper:
Sushentsev N, Arya Z, Budd J et al, AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study, European Radiology 2026: https://t.co/mbhaSyNz7V

[Lucida Medical @LucidaMedical]

A sharper way to assess prostate cancer risk is here.

Pi™ now delivers an integrated risk score combining MRI AI, PSA and PIRADS®. Published evidence shows ~20% fewer unnecessary biopsies with maintained csPCa detection.

Full announcement: https://t.co/vZrfKcHCAc

[Lucida Medical @LucidaMedical]

Read about PAIR-1: https://t.co/9ZxkZ3FLuu

[Lucida Medical @LucidaMedical]

Our PAIR‑1 study was ranked among the Top 5 most downloaded articles in European Radiology for 2025!

At ECR, Prof. Anwar Padhani (@ProfPadhani ) received the official acknowledgment on behalf of all collaborators for this achievement.

Thank you for your support!

[Lucida Medical @LucidaMedical]

Lucida Medical has secured £8.7m in funding led by IW Capital, with participation from XTX Ventures and Macmillan Cancer Support. This investment will advance our patented AI for prostate cancer diagnosis and support our international expansion.

https://t.co/WGl4yHLX68

[Lucida Medical @LucidaMedical]

We will be at ECR 2026, 4-8 March 2026!

📍 Booth location: AI‑32, AI Exhibition Area
🔗 Book a meeting with our team: https://t.co/x4ETEeI3el

We look forward to meeting colleagues and partners in Vienna to discuss how evidence‑based AI can strengthen prostate cancer care.

[Lucida Medical @LucidaMedical]

AI decision support in prostate MRI can boost accuracy, cut variability, and sharpen decisions on PI‑RADS 3 cases.

The challenge is using AI insight without slipping into automation bias.

How do you see this shaping everyday reporting?

[Lucida Medical @LucidaMedical]

We welcome Dr. Luca Russo as Clinical Lead on our Medical Advisory Board!

He is a Radiologist at Gemelli Hospital, a Clinical Research Fellow at The Royal Marsden in London, and holds a PhD in Oncological Sciences.

His expertise will further strengthen our clinical impact!

[Lucida Medical @LucidaMedical]

2025 has been a year of progress at Lucida Medical: new clinical validations, product upgrades, partnerships, and impactful congresses.

With trust, passion and vision, we look forward to 2026, driving innovation and reaching new milestones in the prostate care pathway.

[Lucida Medical @LucidaMedical]

When AI acts as a second reader, MDTs gain safety checks but face new risks: bias, trust gaps, overdiagnosis.

How can teams strike balance between AI’s sensitivity & human judgment in biopsy decisions?

Full paper: https://t.co/f5ivBFI4ar

[Lucida Medical @LucidaMedical]

For this year’s Christmas party, we gathered at King’s College in Cambridge 🎄

The setting was iconic, but what mattered most was the chance to pause and see each other.

We close the year proud of the progress made, and we are excited for the milestones ahead!